

8th February, 2024

The Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers
1st Floor, New Trading Ring
Rotunda, Dalal Street,
Mumbai - 400 001
(BSE Scrip Code: 500187)

The Secretary,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C-1, G-Block
Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051
(NSE Symbol: AGI)

Dear Sir/Madam,

Sub: Newspaper Publication of Financial Results for the quarter and nine months ended 31st December, 2023

Pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith, the newspaper advertisement for the Financial Results of the Company for the quarter and nine-months ended 31st December, 2023, published in “Financial Express” (English newspaper) and “Ekdin” (Regional newspaper).

The same is also available on the website of the Company i.e. www.agigreenpac.com.

You are requested to take this information on records.

For AGI Greenpac Limited
(Formerly known as HSIL Limited)

(Ompal)
Company Secretary
Name: Ompal
Address: 301-302, 3rd Floor, Park Centra, Sector-30, Gurugram-122001
Membership No.: A30926

AGI Greenpac Ltd (formerly known as HSIL Ltd.)

Corporate Office: 301-302, 3rd Floor, Park Centra, Sector-30, NH 8, Gurugram, Haryana-122 001, India. T. +91 124 477 9200

Registered Office: 2, Red Cross Place, Kolkata-700001, West Bengal, India. T. +91 33-22487407/5668 hsilinvestors@hsilgroup.com | www.agigreenpac.com

| CIN: L51433WB1960PLC024539

AGI glaspac Office: Glass Factory Road, Off Motinagar, Borabanda, Hyderabad-500018, India. T: + (91) 40-2383 1771(5lines), M: agi@agi-glaspac.com

AGI Plastek Office: AGI glaspac Premises, Glass Factory Road, Off Motinagar, Borabanda, Hyderabad-500018, India. T: +91 40-2383 1771(5lines), M: sales@gpoly.in

AGI CloZures Office: Sy.No.208 to 218, Sitarampur, Isnapur, Patancheru, Telangana- 502307, India. T: +91-8455-225511, M: info@agiclozures.com

India's own CAR-T cell therapy sees first cure against cancer

Immune system reprogrammed to fight the disease

RUPSA CHAKRABORTY
Mumbai, February 6

A YEAR AGO, if someone had told Dr (Col) VK Gupta, 64, that he would not just be declared "free of cancer cells" — despite a failed bone marrow transplant in 2022 — but would be able to get back to work in 2024, he would have brushed it off as polite optimism.

Months after India's drug regulator approved the commercial use of CAR-T cell therapy, a pioneering treatment that genetically reprogrammes a patient's immune system to fight cancer, Gupta, a Delhi-based gastroenterologist, became one of the first patients to access the therapy by paying ₹42 lakh — a treatment that costs approximately ₹3-4 crore abroad. Doctors at the Tata Memorial Hospital, where he underwent the procedure, said he is "currently free of cancer cells", the first commercial patient to achieve that status.

"While it's premature to claim a lifelong cure, the patient is currently free of cancer cells," said Dr Hasnukh Jain, hemato-oncologist and associate professor at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, who performed the CAR-T cell therapy on Gupta.

Asked about the therapy's success rate, he stressed that the initial findings suggest "better survival chances and lower remission rates" for



Doctors at the Tata Memorial Hospital, where V K Gupta (inset) underwent the indigenous procedure, said the patient is 'currently free of cancer cells', the first commercial patient to achieve that status

patients in early stages of cancer. "We will need two years to determine the treatment's success level. So far, all the patients who underwent this therapy at our hospital are in complete cancer remission with no cancer signs detectable through diagnostic tests. Years of data are needed to identify potential relapse timelines for patients, if any are ever reported among these patients," he said, adding that this advanced gene therapy is expected to "reduce cancer-related mortality, revolutionise cancer treatment and save hundreds of lives".

NexCAR19, the indigenously developed therapy that Gupta underwent, is a treatment for B-cell cancers (types of cancers that form in the immune system's cells) such as leukaemia and lymphoma. It has been developed collaboratively by ImmunoACT, a company incubated at the Indian Institute of Technology Bom-

bay (IITB), IIT-B and Tata Memorial Hospital.

The commercial use of this therapy was approved by the Central Drugs Standard Control Organisation (CDSCO) in October 2023. Currently, NexCAR19 is available in over 30 hospitals in more than 10 cities in India. Patients over the age of 15 years who suffer from B-cell cancers are eligible for this one-time therapy at these centres.

Gupta, who served as a doctor in the Army for 28 years, suffered from acute lymphoblastic leukaemia, a rapidly growing cancer that impacts white blood cells, specifically lymphocytes. "When my (bone marrow) transplant failed (in 2022)...as a doctor myself, I knew I only had a few months left to live. But the CAR-T cell therapy saved me. I feel like a soldier now — tired, but unwilling to give up," he told *The Indian Express*.

Bumrah's workload key issue for India think tank ahead of busy cricket season

Squad for remaining three Tests yet to be announced

VENKATA KRISHNA B
Visakhapatnam, February 6

WITH A DECENT break before the third Test and the five-match series locked 1-1, the biggest concern for India is how their biggest match-winner Jasprit Bumrah shapes up in the next week.

India are yet to name the squad for the remaining three Tests. Though Bumrah is certain to make it, the lingering question is when to give him a rest. Last week, despite Mohammed Siraj bowling full throttle at the nets two days before the Test, India's think-tank decided to send him home from Vizag.

He could have avoided taking the flight to Vizag in the first place, which would have given him a few extra days to spend at home. But it was a decision they took at the eleventh hour, keeping the larger picture of workload in mind and it wasn't just that of Siraj, but also Bumrah. With both needed for the final Test in Dharamsala, India have to use them judiciously at Rajkot or Ranchi, where they will pair up again.

In the two Tests so far, apart from Ravichandran Ashwin on the fourth morning in Vizag, no Indian bowler has embraced the threat of Bazball as much as Bumrah. In both matches, it is Bumrah who has broken England's back. And after failing to find support from the other end in Hyderabad, he single-handedly demolished them in the first innings at Vizag before Ashwin played his part in the second innings.

For England, who seem to have an answer for everything that India throw up, they are yet to find a way to tackle Bum-



INDIA'S TRUMP CARD AGAINST BAZBALL

■ At the moment, it seems as if Bumrah is the lone trump card India have in their hands to counter Bazball as in both matches, it is Bumrah who has broken England's back

■ With a nine-day gap before the third Test in Rajkot, with the series level at 1-1 and momentum by their side, playing Bumrah is tempting for the team management

■ Given Bumrah's importance, there is every reason for India to be concerned about his workload, particularly given the gruelling schedule ahead of them

rah's magic deliveries and combating his reverse-swing would be their sole focus as they head to Abu Dhabi to reunite with their families and enjoy a break.

"Bumrah bowled a fantastic spell of reverse-swing," head coach Brendon McCullum told *BBC Sport*. "Our guys have so much talent and quality, it's just a matter of ensuring they feel confident to make decisions and go all in on their strategies. We need to come up with some ways to counter that."

At the moment, it seems as if Bumrah is the lone trump card India have in their hands to counter Bazball. And it is also the reason why the hosts are taking utmost care of their lead pacer. So much so that trainer S Rajnikanth, who handled his rehabilitation, continues to look after him here. The question India are facing now is whether to rest Bumrah at Rajkot or at Ranchi.

With a nine-day gap before the third Test at Rajkot, with the series level at 1-1 and

momentum by their side, playing Bumrah is tempting for the team management.

Having drawn level, India understand the need to go hard at England at Rajkot and for that they need Bumrah, who delivered every time Rohit Sharma handed him the ball. Although he didn't show any signs of fatigue or struggle, the 33.1 overs he sent down at Vizag is the most he has delivered in a Test since his comeback.



In the six home Tests he has

featured so far, only in the first Test against England during the 2021 series has Bumrah bowled more overs than Vizag. After sending down 42 overs in Chennai, he was rested for the next Test.

Given Bumrah's importance, there is every reason for India to be concerned about his workload, particularly given the gruelling schedule ahead of them. Apart from the IPL, there is a T20 World Cup that follows soon after and then there are eight more Tests lined up this year, including four in Australia, where he would be needed much more. While Bumrah has featured in four consecutive Test matches in a series once each in Australia and England, it was before he went down with a career-threatening back injury.

While India have been handing him short bursts, at Vizag with Mukesh Kumar unable to create any sort of impact with either new or old ball, Rohit had to rush to Bumrah at least on a couple of occasions immediately after a spell. On day two, after a four-over spell, they had to turn to him after just three overs. It meant, at times, even Bumrah wasn't at his absolute best.

So far, Bumrah had been able to hunt in packs, but with Mohammed Shami not around and Umesh Yadav and Ishant Sharma out of favour, he is now carrying the pace department on his shoulders. At all times in this series, with England being at their aggressive best, Bumrah has picked up 15 wickets at an average of 10.66, which is largely down to how attacking he has been. That England are showing him due respect, even prepared to see out his spell — that they have not been able to always do it is a different story — is a testament to how they see Bumrah to be their only threat.

PAT


26% YoY
₹ 67 Cr.

EBITDA

36% YoY
₹ 153 Cr.

REVENUE

10% YoY
₹ 622 Cr.



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31 DECEMBER 2023

(₹ in Crore)

Sr. No.	Particulars	3 months ended 31 December 2023	Corresponding 3 months ended 31 December 2022	Year to date figures for current period ended 31 December 2023	Year to date figures for corresponding period ended 31 December 2022	Year ended 31 March 2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	622.26	567.30	1,796.01	1,601.16	2,281.48
2	Net profit from ordinary activities before tax	90.92	69.08	250.69	171.17	304.04
3	Net profit from ordinary activities after tax	67.12	53.09	186.75	152.84	248.68
4	Net profit for the period after tax (after exceptional/extraordinary items)	67.12	53.09	186.75	152.84	261.63
5	Other comprehensive income/ (expenditure) (net of tax)	(0.03)	0.32	(0.05)	0.97	(13.22)
6	Total comprehensive income	67.09	53.41	186.70	153.81	248.41
7	Equity share capital	12.94	12.94	12.94	12.94	12.94
8	Reserves (excluding revaluation reserve/business reconstruction reserve) as shown in the audited balance sheet of the previous year					1,344.56
9	Earning per share (before extraordinary items) (Continuing Operations) (of ₹ 2/- each) (not annualized)					
	(a) Basic (₹)	10.37	8.23	28.86	23.64	38.45
	(b) Diluted (₹)	10.37	8.23	28.86	23.64	38.45
10	Earning per share (after extraordinary items) (Discontinued Operations) (of ₹ 2/- each) (not annualized)					
	(a) Basic (₹)	-	(0.02)	0.00	(0.02)	1.99
	(b) Diluted (₹)	-	(0.02)	0.00	(0.02)	1.99




Notes:

(1) The Audit Committee has reviewed these results and the Board of Directors have approved the above results and its release at their respective meetings held on 6 February 2024.


(2) The above is an extract of the detailed format of financial results for the quarter and period ended 31 December 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the quarter and period ended 31 December 2023 is available on the websites of the Stock Exchanges (www.bseindia.com and www.nseindia.com) and on the Company's website "www.agigreenpac.com".

Place : Gurugram
Date : 6 February, 2024

Sandip Somany
Chairman and Managing Director

AGI GREENPAC LIMITED (FORMERLY KNOWN AS HSIL LIMITED)
Regd. Office: 2, Red Cross Place, Kolkata-700 001, Tel: 033-22487407/5668
Website: www.agigreenpac.com | Email: hsilinvestors@hsilgroup.com | CIN : L51433WB1960PLC024539



EASY TRIP PLANNERS LIMITED

CIN: L6309DL2008PLC179041

Registered Office: 223, FIE Patparganj Industrial Area Delhi 110092, India
Website - www.EaseMyTrip.com | email - emt.secretarial@easemytrip.com

NOTICE OF POSTAL BALLOT

Members are hereby informed that pursuant to the provision of section 108 and 110 and other applicable provision of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014 (cumulatively "Act"), SEBI (Listing Obligations and Disclosure Requirements) 2015, ("Listing Regulation"), Secretarial Standards-2 issued by the Institute of Companies Secretaries of India and other applicable laws and regulations, if any, including any statutory modification(s) or re-enactment thereof for the time being in force, Easy Trip Planners Limited ("the Company") is seeking approval from the members via passing of Resolution as set out in the Postal Ballot Notice dated February 06, 2024 ("Postal Ballot Notice") by the way of electronic voting ("e-voting/remote e-voting") only.

In terms of the relevant provisions of the Act and in accordance with the guidelines issued by the Ministry of Corporate Affairs, inter-alia, for conducting Postal Ballot through e-voting vide General Circulars Nos. 14/2020, 17/2020, 22/2020, 33/2020, 39/2020 and 10/2021 dated April 8, 2020, April 13, 2020, June 15, 2020, September 28, 2020, December 31, 2020 and June 23, 2021 respectively ("MCA Circulars"), the process of sending the Postal Ballot Notice along with the instructions regarding remote e-voting through email to all those Members, whose email address is registered with the Company or with the Depositories/Depository Participants or M/s. KFin Technologies Limited ("KFIN or KFinTech"), Register and Share Transfer Agents of the Company ("R&TA") and whose names appear in the Register of Members/list of Beneficial Owners as on Friday, February 02, 2024 ("Cut-off Date"), has completed February 02, 2024. A person who is not a member on the cut-off date should accordingly treat the Postal Ballot Notice for the information purposes only.

In compliance with the requirements of the MCA Circulars, physical copy of the Postal Ballot Notice along with Postal Ballot Forms and pre-paid business envelope will not be sent to the shareholders for this Postal Ballot and shareholders are required to communicate their assent and dissent through the e-voting system only.

All the Members are hereby informed that:

- The e-voting period shall commence on Wednesday, February 07, 2024 at 09:00 a.m. (IST) and ends on Thursday, March 07, 2024 at 05:00 p.m. (IST) for all the shareholders holding shares in physical form or demat form. The e-voting module shall be disabled by NSDL for the voting thereafter. Remote e-voting shall not be allowed beyond the said time and date.
- A person whose name is recorded in the register of members or in the register of Beneficial Owners maintained by the depositories as on the cut-off date i.e Friday, February 02, 2024, shall be entitled to avail the facility of remote e-voting.
- The company has appointed Mrs. Manisha Gupta (Membership No.: FCS 6378 COP No.: 6808), Proprietor of M/s. Manisha Gupta & Associates, Practicing Company Secretaries, New Delhi, as Scrutinizer for conducting the Postal Ballot through remote e-voting process in a fair and transparent manner.
- The result of the Postal Ballot/e-voting will be declared on or before Saturday, March 09, 2024 (05:00 p.m.) at the Corporate Office of the Company by the Chairman or any other person authorized by him on that behalf. The result along with then scrutinizer's report shall be placed on the website of the company and on the website of NSDL and communicated to the Stock Exchanges where the Company's shares are listed.

If you have not registered your email address with the Company/Depository, you may please follow the below instructions:

- Physical shareholders- please provide the necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested) copy of PAN card), AADHAR (self-attested copy of Aadhar Card) by email to Company at emt.secretarial@easemytrip.com and/or RTA email at einward.ris@kfin.tech.com.
- Demat shareholders- Please update your email id & mobile no. with your respective Depository Participant (DP).

Post successful registration of the email, the member would get a soft copy of the notice and the procedure for e-voting along with the User ID and Password to enable e-voting for this Postal Ballot. In case of any queries, member may write to evoting@nsdl.com

For further details, kindly refer to the notice of Postal Ballot. The notice is also available on the Company's website (www.easemytrip.com), Stock Exchanges' website (www.bseindia.com and www.nseindia.com) and on the service provider i.e. NSDL's website of evoting@nsdl.com

If you have any queries or issues regarding e-voting from the NSDL e-voting System, you can write an email to o evoting@nsdl.com or contact at toll free number 1-800-309-4001

For Easy Trip Planners Limited
Sd/-
Priyanka Tiwari
Group Company Secretary and Chief Compliance Officer

Date: February 06, 2024
Place: Delhi

financialexp.in

Kolkata

